SCHEMBL4677635

SCHEMBL4677635

COCCOc1cc(F)c(CO)c(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.37
RORC P51449 1/20 0.35
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35
PRKAG2 Q9UGJ0 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
SLC6A4 P31645 1/20 0.34
ALDH2 P05091 1/20 0.34
FFAR1 O14842 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
FGFR1 P11362 2/20 0.34
FLT1 P17948 2/20 0.34
POLB P06746 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HTT P42858 1/20 0.33
RECQL P46063 1/20 0.33
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4682530 0.92 SLC6A4 (0.39) KDRSLC6A4FFAR1TAAR1POLB
SCHEMBL4684332 0.89 TAAR1 (0.39) KDRFFAR1TAAR1FGFR1FLT1
SCHEMBL4678195 0.86 HTT (0.36) FFAR1L3MBTL1HTTRECQLCYP1A2
SCHEMBL4677644 0.84 HTT (0.44) HTTRECQLKDM4ETSHR
SCHEMBL17197091 0.84 GPBAR1 (0.37) FFAR1TAAR1RECQLLMNAKDM4E
SCHEMBL4678875 0.82 NQO1 (0.34) FFAR1TAAR1POLBKDM4ETDP1
SCHEMBL15544932 0.82 TAAR1 (0.52) TAAR1HTTLMNAKDM4ECYP1A2
SCHEMBL23378586 0.76 L3MBTL1 (0.38) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL4681126 0.75 HTR2C (0.36) LMNATSHR
SCHEMBL4680859 0.75 GSTP1 (0.37) HTTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343775-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-06-04 EP disclosed
US-7022707-B2 Piperazine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20040235859-A1 Novel piperazine derivatives ADAMS DAVID REGINALD (GB) 2004-11-25 US disclosed
EP-1343775-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-17 EP disclosed
US-20020143020-A1 Novel piperazine derivatives VERNALIS RESEARCH LIMITED (GB) 2002-10-03 US disclosed
WO-2002048124-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143020-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 KDR 1806/4885RORC 435/4885PRKAB2 3392/4885
US-20040235859-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 KDR 1806/4885RORC 435/4885PRKAB2 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.